NewtekOne Q2: The Strategy That Looks Right Until You Check the Credit

NewtekOne (NEWT) told investors on its Q2 earnings call that it is fundamentally changing how it makes money. Less gain-on-sale revenue from flipping SBA loans into the secondary market. More recurring net interest income from holding those loans on the bank's balance sheet. It sounds like the right evolution for a small-business lender that has spent years trading off origination volume rather than building an asset book.

The stock fell 9.5% the day after the report and another 8.8% over the following five trading days, closing at $13.53. The factor stack explains why the market discounted the turnaround story.

Valuation — C+: Looks cheap until you check what you're buying

NEWT trades at 6.4 times trailing earnings and 0.97 times book value. Against small-cap banking peers — WSFS Financial at 13x earnings and 1.5x book, First Bancorp at 20x and 1.6x — the discount looks enormous. The 5.6% dividend yield adds a floor that most growth stories don't offer.

But a cheap multiple is not a thesis. It's a starting question. The market assigns a discount when earnings quality is uncertain or credit risk is rising. In this case, both are live questions. Q2 diluted EPS of $0.47 beat consensus of $0.46, but that's down from $0.52 a year ago. Revenue grew 7% to $75.1 million, but the company withdrew its Q4 2026 guidance entirely, saying it needs 45–60 days to model the new revenue composition. When a company can't quantify its own future earnings because it's rewriting its business model, the cheap multiple starts to look like compensation for that uncertainty, not an arbitrage.

Growth — B-: The engine switched, but the speed is unproven

This is where the strategic shift shows up in the numbers. Bank net interest income jumped to $25 million from $16.2 million a year earlier. Deposits hit $2.2 billion, up from $142 million over the preceding 14 quarters — a deposit franchise that went from negligible to material. Core consumer deposits grew 21% quarter-over-quarter and 124% year-over-year.

Revenue growth of 8.9% year-over-year is solid. But operating expenses grew too, and the efficiency ratio only improved from 60% to 58%. More important, the growth mix is changing. Gain-on-sale income — which was predictable when the pipeline was flowing — is being replaced by net interest income, which depends on credit quality holding. Q2 revenue came in above consensus, but the sequential dip of 3.2% quarter-over-quarter suggests the transition isn't frictionless.

Profitability — C: ROAA tells the story the headline doesn't

Return on average assets fell to 1.97% from 2.58% a year ago. Pre-provision net revenue (a measure of operating income before credit losses are set aside) declined from 5.25% to 4.22% of average assets. Return on equity stands at 19.3%, which is respectable, but that's propped up by the company's extreme leverage — debt-to-equity of 136%. For a bank holding company, that's the normal structure. For a reader evaluating profitability quality, it means the ROE number carries more balance-sheet risk than it implies.

Tangible book value per share rose 15% year-over-year to $12.13 and is up 75.3% over the past 12 quarters since the company's REIT conversion. That trajectory is the one metric in this quarter that argues for durability. The problem is the stock at $13.53 now trades above tangible book. The "deep discount to TBV" narrative that supported the stock for months has evaporated.

Safety — D: Credit is the load-bearing concern

This is the factor that changed the market's mind. Accruing SBA 7(a) loans 30+ days past due jumped to 3.99% from 2.39% in the prior quarter — a 67% increase in delinquency rate in three months. Management responded by building reserves: the allowance for credit losses as a percentage of loans held for investment rose to 5.31% from 5.10%. Eighty-nine percent of the total allowance is allocated to unguaranteed SBA 7(a) exposure.

Nonperforming loans (excluding government guarantees) edged down to 4.14% from 4.36%, which is a positive, but that metric is backward-looking. The delinquency curve is forward-looking. When 30+ day delinquencies nearly double in a quarter, charge-offs tend to follow.

Management is diversifying away from SBA concentration — uninsured SBA balances fell from nearly 50% of the portfolio to 42%. The legacy NSBF portfolio now represents 10% of consolidated loans, down from 19% a year ago. Those are the right moves. But the credit deterioration signal in Q2 is the strongest negative data point in the report, and it's exactly what happens when you hold loans on your balance sheet instead of selling them: someone has to absorb the losses. Now it's NewtekOne.

Momentum — D-: The trend reversed

RS-14 sat at 36.8, well below the 50-level that separates bullish from bearish momentum. The 50-day moving average is at $14.32, above the current price. Over five days the stock lost 8.8%; over 20 days, 8.5%. Year-to-date it had gained 19.2%, but that rally is now in the rearview. The 52-week range spans $9.59 to $15.69, and NEWT is trading closer to the middle than the top. Zacks assigned a Rank #4 (Sell) based on negative estimate revisions. AInvest's aggregate signal labels the stock Hold.

Momentum is not a standalone thesis, but it confirms that institutional money is rethinking the risk/reward after this quarter.

The portfolio role

NEWT doesn't fit cleanly into any sleeve right now. It's not a dividend income play — the 5.6% yield looks comfortable until credit losses compress the earnings that fund it. It's not a growth play — the transition from gain-on-sale to net interest income is a structural change with unproven durability. It's not a pure value play — the cheap multiple reflects real credit risk, not market inefficiency.

What it is: a turnaround candidate that needs one or two quarters of stable credit metrics to re-earn its valuation. The Q4 securitization of $300–$400 million would recycle capital and prove the balance sheet model works at scale. The withdrawn guidance means there's no consensus anchor to measure progress against until management speaks again in roughly 60 days.

The trade case for NEWT is directional: if SBA delinquencies stabilize below 4% and net interest income holds above $25 million, the stock re-rates toward its book value and the 6x earnings multiple expands. If delinquencies accelerate into the 5% range, charge-offs will compress earnings and the current price is defensible.

The factor stack right now leans Hold. The valuation discount has narrowed. Credit quality is the open question. Wait for the 60-day guidance update and the next quarter's delinquency numbers before adding to this position. A stock trading below its 50-day average with rising SBA delinquencies isn't a screaming buy — it's a watchlist name with a defined catalyst on the horizon.